Oruka Therapeutics (ORKA) AI Stock Analysis

• Market Cap: $1.55B
• Dividend Yield: N/A
• Average Volume (3M): 530.53K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.84
• Revenue Growth: N/A
• EPS Growth: 63.85%
• Country: US
• Employees: 28
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.55
• Shares Outstanding: 48,409,233
• 10 Day Avg. Volume: 602,310
• 30 Day Avg. Volume: 530,527
• PEG Ratio: -0.31
• Price to Book (P/B): 0.85
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -5.61
• Enterprise Value/Market Cap: 0.10
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -1.31
• 1Y Price Target: $57.80
• Price Target Upside: 77.85% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 11
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 41 Neutral
• Price Target: ―

Oruka Therapeutics faces significant challenges typical of early-stage biotech companies, such as ongoing losses and negative cash flow. The technical indicators reflect a bearish trend, while the negative P/E ratio underscores valuation difficulties. The lack of guidance or sentiment from the latest earnings call adds to the uncertainty. The strong equity base provides some financial stability, but the stock's performance is closely tied to future product development success.

Positive Factors

Strong Equity Base

A strong equity base with low debt provides financial stability, allowing Oruka to focus on long-term R&D without immediate financial pressure.

Executive Stability

Adjusting executive severance agreements ensures leadership stability, which is crucial for strategic continuity and investor confidence in long-term plans.

Improved Cash Management

Improved cash management, despite negative cash flow, suggests operational efficiency and prudent financial practices, supporting long-term sustainability.

Negative Factors

Ongoing Operational Losses

Persistent operational losses reflect challenges in achieving profitability, which can strain resources and delay progress in product development.

Negative Cash Flow

Negative cash flow limits financial flexibility and may necessitate additional funding, impacting the company's ability to invest in growth initiatives.

Lack of Revenue Generation

The absence of revenue generation due to the R&D stage limits the company's ability to achieve profitability and sustain operations without external funding.

Oruka Therapeutics Business Overview & Revenue Model

Company Description

Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

How the Company Makes Money

Oruka Therapeutics generates revenue primarily through the development and commercialization of its proprietary therapeutic products. The company earns money by licensing its technologies and compounds to larger pharmaceutical firms, entering into strategic partnerships for co-development, and through direct sales of approved therapies. Significant partnerships with research institutions and healthcare providers enable Oruka to expand its reach and accelerate its development processes. Additionally, Oruka may receive milestone payments and royalties from its collaboration partners upon successful achievement of specified development and commercialization goals.

Oruka Therapeutics Financial Statement Overview

Summary

Oruka Therapeutics is in the development stage with no revenue generation, leading to negative EBIT and net income. The company's low debt and strong equity base provide financial stability, but ongoing losses and negative cash flow are concerns.

Income Statement

Oruka Therapeutics consistently reports negative EBIT and Net Income, reflecting ongoing operational losses typical for early-stage biotechnology firms. The absence of revenue due to the R&D stage limits the potential for positive margin metrics.

Balance Sheet

The company maintains a strong equity base with low debt, resulting in a favorable debt-to-equity ratio. High levels of stockholders' equity relative to total assets indicate financial stability, though ongoing losses might erode equity over time.

Cash Flow

Negative operating cash flows are consistent with development-stage biotech companies. However, free cash flow has improved recently, indicating better cash management despite persistent negative figures.

Breakdown	TTM	Dec 2024	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	-27.00K	-114.00K	-91.00K	-93.00K	-89.00K
EBITDA	-113.23M	-82.23M	-9.81M	-19.23M	-9.64M	-5.55M
Net Income	-109.24M	-83.72M	-9.93M	-19.32M	-9.74M	-5.48M
Balance Sheet
Total Assets	509.25M	396.02M	43.09M	54.92M	50.43M	8.54M
Cash, Cash Equivalents and Short-Term Investments	349.15M	375.65M	42.45M	53.36M	49.07M	8.36M
Total Debt	1.91M	968.00K	383.00K	483.00K	450.00K	25.00K
Total Liabilities	22.46M	13.80M	1.41M	3.88M	3.91M	926.00K
Stockholders Equity	486.79M	382.22M	41.67M	51.04M	46.52M	7.61M
Cash Flow
Free Cash Flow	-84.60M	-58.03M	-10.91M	-18.80M	-7.74M	-4.80M
Operating Cash Flow	-84.43M	-57.84M	-10.91M	-18.76M	-7.72M	-4.80M
Investing Cash Flow	-404.68M	-330.13M	-2.00K	-43.00K	-19.00K	-4.00K
Financing Cash Flow	169.49M	449.54M	0.00	23.09M	48.45M	6.56M

Oruka Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 32.50
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ORKA, the sentiment is Positive. The current price of 32.5 is above the 20-day moving average (MA) of 29.83, above the 50-day MA of 29.33, and above the 200-day MA of 18.34, indicating a bullish trend. The MACD of 0.38 indicates Negative momentum. The RSI at 60.51 is Neutral, neither overbought nor oversold. The STOCH value of 96.80 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ORKA.

Oruka Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CMPX	58 Neutral	$1.07B	-12.67	-37.82%	―	-100.00%	-28.79%
OLMA	56 Neutral	$2.26B	-16.11	-59.22%	―	―	17.23%
BCAX	56 Neutral	$987.17M	-7.49	-26.64%	―	―	-103.95%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ANAB	49 Neutral	$1.39B	-16.43	-308.02%	―	196.42%	53.92%
VSTM	48 Neutral	$511.42M	-1.55	-2888.70%	―	33.79%	-26.37%
ORKA	41 Neutral	$1.55B	-13.45	-23.05%	―	―	63.85%

Oruka Therapeutics Corporate Events

Oruka Therapeutics Appoints Christopher Martin to Board

On December 11, 2025, Oruka Therapeutics, Inc. announced the resignation of Cameron Turtle from its Board of Directors, which was not due to any disagreements or removal for cause. Concurrently, Christopher Martin was appointed as a Class II director and took on roles as Chair of the Compensation Committee and a member of the Audit Committee. Martin brings extensive experience from his previous roles, including his tenure as Chief Commercial Officer at Verona Pharma, which was recently acquired by Merck & Co. His appointment is expected to strengthen Oruka’s strategic direction and governance.

The most recent analyst rating on (ORKA) stock is a Buy with a $45.00 price target. To see the full list of analyst forecasts on Oruka Therapeutics stock, see the ORKA Stock Forecast page.